ATXI - Avenue Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
+0.08 (+1.50%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close5.33
Bid5.20 x 1100
Ask5.90 x 1000
Day's Range5.26 - 5.41
52 Week Range2.08 - 6.82
Avg. Volume45,355
Market Cap89.277M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.10
Earnings DateFeb 27, 2019 - Mar 4, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.67
Trade prices are not sourced from all markets
  • GlobeNewswire13 days ago

    Avenue Therapeutics Reports Full Year 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, March 12, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

  • GlobeNewswirelast month

    Avenue Therapeutics Announces First Stage Closing of its Acquisition Agreement with InvaGen (a Cipla subsidiary)

    NEW YORK, Feb. 11, 2019 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a Fortress Biotech (NASDAQ: FBIO) company, today announced the completion of the first stage.

  • Zacks Small Cap Research2 months ago

    ATXI: How Much Are CVRs Worth?

    Avenue Therapeutics (ATXI) will hold its special meeting of shareholders on February 6, 2019 to consider the stock purchase and merger agreement proposed by InvaGen Pharmaceuticals. On November 13, 2018, Avenue announced an acquisition with InvaGen Pharmaceuticals which will initially provide $35 million in capital for a one-third stake in the company. Following FDA approval and the desired label, InvaGen will complete its acquisition of the company for an estimated $13.92 per share plus contingent rights to payments related to revenue and profit levels.

  • GlobeNewswire2 months ago

    Stull, Stull & Brody Announces Class Action Suit on Behalf of Purchasers of the Securities of Avenue Therapeutics, Inc. (NasdaqCM: ATXI)

    Stull, Stull & Brody (“SS&B”) announces that a class action lawsuit has been filed and it is investigating the Board of Directors of Avenue Therapeutics, Inc. ("Avenue" or the "Company") (ATXI) for possible breaches of fiduciary duty related to the sale of the company to InvaGen Pharmaceuticals, Inc. and Madison Pharmaceuticals, Inc. Under the terms of the proposed transaction, Avenue shareholders are only anticipated to receive $13.92 for each share of Avenue common stock owned.

  • PR Newswire3 months ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Avenue Therapeutics, Inc. - ATXI

    NEW YORK , Dec. 12, 2018 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • Zacks Small Cap Research4 months ago

    ATXI: InvaGen Acquisition Spices Up Quarterly Report

    By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) released third quarter 2018 financial results and submitted their Form 10-Q to the SEC on November ...

  • GlobeNewswire4 months ago

    Research Report Identifies Chicken Soup for the Soul Entertainment, Allied Motion Technologies, Bandwidth, Solid Biosciences, Avenue Therapeutics, and BeyondSpring with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire4 months ago

    Avenue Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, Nov. 14, 2018 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a specialty pharmaceutical company focused on the development and commercialization of.

  • Zacks Small Cap Research4 months ago

    ATXI: InvaGen Capital Raise & Acquisition

    Avenue Therapeutics (ATXI) announced an acquisition agreement with InvaGen Pharmaceuticals to acquire a 33.3% stake in the company for $35 million to be followed by a second stage closing in 2021 which will acquire the remaining shares for up to $180 million, subject to FDA approval and other specific terms. 5.8 million new shares will be issued at $6 per share, providing sufficient capital to advance IV tramadol to the post-approval stage. Furthermore, if the FDA grants approval and certain milestones are met, shareholders will receive payment of an estimated $13.92 per share and be eligible for contingent post-transaction consideration based on sales and profit metrics.

  • GlobeNewswire4 months ago

    InvaGen (a Cipla subsidiary) Announces Acquisition Agreement with Avenue Therapeutics for Specialty Hospital Business in the U.S.

    MUMBAI, India & NEW YORK, Nov. 13, 2018 (GLOBE NEWSWIRE) -- InvaGen Pharmaceuticals Inc. (“InvaGen”), a subsidiary of the leading global pharmaceutical company Cipla Limited, today announced that it has entered into definitive agreements with two closing stages for a proposed acquisition of Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a Fortress Biotech (FBIO) company focused on the development and commercialization of intravenous (IV) Tramadol. The transaction will be subject to Avenue stockholders’ and regulatory approvals, and other closing conditions.

  • Zacks Small Cap Research7 months ago

    ATXI: Second Quarter 2018 Results

    By John Vandermosten, CFA NASDAQ:ATXI READ THE FULL ATXI RESEARCH REPORT Avenue Therapeutics (NASDAQ:ATXI) provided their press release and their form 10-K including second quarter 2018 financial results ...

  • Reuters8 months ago

    Special Report: Biotech incubator taps investors through in-house brokerage

    Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.

  • Zacks Small Cap Research9 months ago

    ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol

    Avenue Therapeutics (ATXI) hosted a moderated discussion on tramadol on June 11 which featured two key opinion leaders (KOLs) in the space. The participants were Dr. Neil Singla and Dr. Harold Minkowitz. Dr. Singla brings a long history developing analgesic medicines to the discussion.

  • ACCESSWIRE10 months ago

    Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Avenue Therapeutics, Inc. (NASDAQ: ATXI), all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On May 21, 2018, the Company announced that its first pivotal Phase-3 trial assessing IV tramadol for treatment of patients with moderate to moderately severe postoperative pain following bunionectomy surgery achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo. is currently working on the research report for Taro Pharmaceutical Industries Ltd (NYSE: TARO), which also belongs to the Healthcare sector as the Company Avenue Therapeutics.

  • Benzinga10 months ago

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • Zacks Small Cap Research10 months ago

    ATXI: 1Q:18 Update Confirms Timeline

    By John Vandermosten, CFA NASDAQ:ATXI Avenue Therapeutics (NASDAQ:ATXI) circulated a press release and their form 10-K with their first quarter 2018 financial results on May 3rd. Total expenses for the ...

  • Zacks Small Cap Research11 months ago

    ATXI: No Pain? We See a Gain; Developing Tramadol

    Avenue Therapeutics (ATXI) is developing IV tramadol for postoperative pain. Avenue has licensed a patented administration of IV tramadol that is able to limit side effects and provide a solution for moderate to severe pain which avoids many of the risks of opioids and non-steroidal anti-inflammatory drugs (NSAIDs). The drug also allows for transition to step down therapy with oral tramadol, which mirrors the pharmacokinetic, side effect profile and pain control of the IV form.